422 related articles for article (PubMed ID: 27865784)
1. A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.
Sorber L; Zwaenepoel K; Deschoolmeester V; Roeyen G; Lardon F; Rolfo C; Pauwels P
J Mol Diagn; 2017 Jan; 19(1):162-168. PubMed ID: 27865784
[TBL] [Abstract][Full Text] [Related]
2. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of commercial kits for purification of circulating free DNA.
Diefenbach RJ; Lee JH; Kefford RF; Rizos H
Cancer Genet; 2018 Dec; 228-229():21-27. PubMed ID: 30553469
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood.
Kresse SH; Brandt-Winge S; Pharo H; Flatin BTB; Jeanmougin M; Vedeld HM; Lind GE
Clin Epigenetics; 2023 Sep; 15(1):151. PubMed ID: 37710283
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing.
Pérez-Barrios C; Nieto-Alcolado I; Torrente M; Jiménez-Sánchez C; Calvo V; Gutierrez-Sanz L; Palka M; Donoso-Navarro E; Provencio M; Romero A
Transl Lung Cancer Res; 2016 Dec; 5(6):665-672. PubMed ID: 28149760
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cell-free DNA as a biomarker for pancreatic malignancies.
Sikora K; Bedin C; Vicentini C; Malpeli G; D'Angelo E; Sperandio N; Lawlor RT; Bassi C; Tortora G; Nitti D; Agostini M; Fassan M; Scarpa A
Int J Biol Markers; 2015 Feb; 30(1):e136-41. PubMed ID: 24832178
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
[TBL] [Abstract][Full Text] [Related]
10. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.
Takai E; Totoki Y; Nakamura H; Morizane C; Nara S; Hama N; Suzuki M; Furukawa E; Kato M; Hayashi H; Kohno T; Ueno H; Shimada K; Okusaka T; Nakagama H; Shibata T; Yachida S
Sci Rep; 2015 Dec; 5():18425. PubMed ID: 26669280
[TBL] [Abstract][Full Text] [Related]
12. Isolation and Quantification of Plasma Circulating Tumor DNA from Melanoma Patients.
Marsavela G; Reid A; Gray ES; Calapre L
Methods Mol Biol; 2021; 2265():247-263. PubMed ID: 33704720
[TBL] [Abstract][Full Text] [Related]
13. Performance comparison of commercial kits for isolating and detecting circulating tumor DNA.
Wang M; Huang X; Li X; Guo Q; Xu W; Zhao M; Wang X; Wang L; Lou J
Scand J Clin Lab Invest; 2021 Jul; 81(4):276-281. PubMed ID: 33999736
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.
Tjensvoll K; Lapin M; Buhl T; Oltedal S; Steen-Ottosen Berry K; Gilje B; Søreide JA; Javle M; Nordgård O; Smaaland R
Mol Oncol; 2016 Apr; 10(4):635-43. PubMed ID: 26725968
[TBL] [Abstract][Full Text] [Related]
17. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
[TBL] [Abstract][Full Text] [Related]
18. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
19. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
20. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification.
Devonshire AS; Whale AS; Gutteridge A; Jones G; Cowen S; Foy CA; Huggett JF
Anal Bioanal Chem; 2014 Oct; 406(26):6499-512. PubMed ID: 24853859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]